The role of hypoxic signaling in evasive tumor resistance against anti-angiogenic therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Gießen, Justus-Liebig-Universität, Dissertation, 2019
- Keyword
-
Therapeutics
- Event
-
Veröffentlichung
- (where)
-
Gießen
- (who)
-
Universitätsbibliothek
- (when)
-
2020
- Creator
- URN
-
urn:nbn:de:hebis:26-opus-149452
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:19 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Trompak, Omelyan
- Universitätsbibliothek
Time of origin
- 2020
Other Objects (12)
Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma
Metabolic and hypoxic adaptation to anti‐angiogenic therapy: a target for induced essentiality
Resistance to chemotherapy and anti-angiogenic therapy in ovarian cancer
Anti-angiogenic therapies in brain metastases
Anti-angiogenic alternatives to VEGF blockade
Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy
Modulation of adaptive immunity to overcome resistance to anti-angiogenic therapy by inhibition of IL-17 signaling
EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
Tenascin-C orchestrates glioblastoma angiogenesis by modulation of pro- and anti-angiogenic signaling
Characterization of anti-angiogenic therapy response in glioblastoma
Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma
Metabolic and hypoxic adaptation to anti‐angiogenic therapy: a target for induced essentiality
Resistance to chemotherapy and anti-angiogenic therapy in ovarian cancer
Anti-angiogenic therapies in brain metastases
Anti-angiogenic alternatives to VEGF blockade
Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy
Modulation of adaptive immunity to overcome resistance to anti-angiogenic therapy by inhibition of IL-17 signaling
EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
Tenascin-C orchestrates glioblastoma angiogenesis by modulation of pro- and anti-angiogenic signaling
Characterization of anti-angiogenic therapy response in glioblastoma
Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma
Metabolic and hypoxic adaptation to anti‐angiogenic therapy: a target for induced essentiality
Resistance to chemotherapy and anti-angiogenic therapy in ovarian cancer
Anti-angiogenic therapies in brain metastases
Anti-angiogenic alternatives to VEGF blockade
Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy
Modulation of adaptive immunity to overcome resistance to anti-angiogenic therapy by inhibition of IL-17 signaling
EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
Tenascin-C orchestrates glioblastoma angiogenesis by modulation of pro- and anti-angiogenic signaling